Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

October 22, 2020

Study Completion Date

October 22, 2020

Conditions
Pulmonary Vascular Disease
Interventions
DRUG

GE-141, Hyperpolarized 129Xenon gas

XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe

DEVICE

MRI

Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Bastiaan Driehuys

OTHER

NCT03078192 - Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter